Albireo Pharma has announced plans to study elobixibat in a Phase II clinical trial involving adults with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
The drug’s investigational new drug (IND) application has been cleared by the US Food and Drug Administration (FDA).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Elobixibat is a first-in-class, oral, once-daily ileal bile acid transporter (IBAT) inhibitor. The drug has been approved in Japan for the treatment of chronic constipation, except in cases of organic disease.
The Phase II trial will evaluate the safety and efficacy of 5mg elobixibat over 16 weeks in around 46 patients with biopsy-confirmed NASH or suspected NAFLD/NASH based on metabolic syndrome definitions.
Change in low-density lipoprotein (LDL) cholesterol will be measured as the primary endpoint of the randomised, double-blinded, placebo-controlled, multi-centre trial.
Secondary endpoints of the study include assessment of change in liver fat by imaging, and the levels of alanine transaminase (ALT) and serum bile acids.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe firm will launch the trial in the second quarter of this year and results are expected next year.
Albireo Pharma president and CEO Ron Cooper said: “The IND and subsequent trial initiation are an important step for our NASH programme, as we apply our expertise in bile acids and leverage our novel IBAT platform to address a large unmet medical need.
“We have a two-pronged approach for NASH development: advancing elobixibat, a well-characterised IBAT inhibitor, into a Phase II trial, and continuing to develop novel preclinical compounds.”
NAFLD is known to impact approximately 25% of people globally. The disease could progress to NASH that causes liver inflammation and damage due to accumulation of fat in the organ.
Risk of liver-related mortality in patients with NASH is ten times greater than the general population and the condition currently lacks approved pharmacologic treatments.
